Sg3 Management, LLC Prothena Corp Public LTD CO Put Options Transaction History

Sg3 Management, LLC

9 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q4 2020 Feb 16, 2021	SELL	$10.12 - $13.94 $50,599 - $69,700	-5,000 Reduced 20.0%	20,000 $240,000
Q3 2020 Nov 13, 2020	BUY	$9.93 - $13.47 $248,250 - $336,750	25,000 New	25,000 $250,000
Q4 2017 Feb 13, 2018	SELL	$35.44 - $63.76 $496,159 - $892,640	-14,000 Closed	0 $0
Q3 2017 Feb 26, 2018	BUY	$53.83 - $67.75 $746,083 - $939,015	13,860 Added 9900.0%	14,000 $907,000
Q3 2017 Jan 25, 2018	SELL	$53.83 - $67.75 $746,083 - $939,015	-13,860 Reduced 99.0%	140 $29,000
Q2 2017 Feb 26, 2018	BUY	N/A	13,860 Added 9900.0%	14,000 $758,000
Q2 2017 Jan 25, 2018	SELL	N/A	-13,860 Reduced 99.0%	140 $118,000
Q1 2017 Feb 26, 2018	BUY	N/A	13,860 Added 9900.0%	14,000 $781,000
Q1 2017 Jan 25, 2018	BUY	N/A	140	140 $144,000

184

42.7M

162K

102K

Ticker PRTA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,922,800
Market Cap $745M
Description
Prothena Corporation plc, a late-stage clinical company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States. The company is involved in developing Birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a human...

Get notified when there are updates to the investment portfolio of Sg3 Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Sg3 Management, LLC with notifications on news.